Roche

PLEASANTON, California, December 16, 2011 - - The test confidently detects HLA-B*5701 to help decrease risk of abacavir hypersensitivity reaction Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its HLA-B*5701 screening test[1] is now commercially available in Europe.

LONDON, November 17, 2011 - As the new cobas HPV test from Roche is accepted for the national cervical cancer screening programme in England for use at triage, further research also supports the use ofRoche's cobas HPV test in"primary"screeningas part of a more sensitive and more efficient strategy in the fight against cervical cancer Data from a sub-analysis of the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) landmark study, recently published online in The Lancet Oncology, demonstrated that the Roche cobas HPV Test, could be used for the primary screening of cervical cancer.

BERLIN, September 19, 2011 - - Data demonstrate thecobasHPV Test, with its option of individual HPV 16 and 18 genotyping, provides additional risk stratification for high risk HPV-positive women - A separate study by Dutch HPV experts validates the cobasHPV Test for use in primary screening utilizing its ability to detect 14 high risk HPV types Roche (SIX: RO, ROG; OTCQX: RHHBY) today highlighted data from a sub-analysis of the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) landmark study, demonstrating that HPV DNA tests, including the Roche cobas HPV Test, could be used for the primary screening of cervical cancer.

PLEASANTON, California, August 23, 2011 - - cobas BRAF Mutation Test is used to identify patients with melanoma tumors that harbor a genetic mutation which can be treated with Zelboraf (vemurafenib) Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas BRAF Mutation Test is now commercially available in Europe and in countries that recognize the CE mark.

LONDON, June 6, 2011 - - Launch of 'my diary from down under' by Nikki Bayley In the UK, 20 per cent of women still do not attend smear tests, putting themselves at risk of leaving pre-cancerous cervical cells undetected[i].